Searched for
DIVI S LABORATORIES
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...- More women CXOs join India’s million-dollar pay club as domestic firms lead compensation growthNine women now earn over one million dollars annually as C-suite executives. Domestic companies are leading this rise, reflecting a focus o...
- For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...
- Divi's Laboratories Q4 Results: Cons PAT grows 13% YoY to Rs 751 crore, revenue up 10%; Rs 30 per share dividend announcedDivi's Laboratories Q4 Results: Divi's Laboratories announced strong financial results for the March quarter. Net profit rose 13% to Rs 751...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Pharma, NBFCs see fresh mutual fund buying in AprilIndian fund managers focused on defensive stocks in April. Pharmaceuticals saw increased investment due to opportunities like the semagluti...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Positive Breakout: These 8 stocks cross above their 200 DMAsAs long as the stock is priced above the 200-day SMA on the daily timeframe, it is generally considered to be in an overall uptrend.
- Saurabh Mukherjea has moved half his personal portfolio out of India; here's whySaurabh Mukherjea, founder of Marcellus Investment Managers, has shifted his personal portfolio to a 50-50 split between Indian and global ...
- Divi’s Laboratories Q4 results: PAT surges 26% YoY, revenue up 12%Divi's Laboratories announced a robust financial performance for the March quarter of FY25, with a 25.6% YoY surge in standalone net profit...
- Divi’s Laboratories: SidewaysDivi’s Laboratories’ daily trend is sideways. The RSI for monthly, weekly and daily are showing sideways momentum. Based on option chain an...
- Divi's Labs shares drop 2% on brokerage downgrades post Q1 result. Should you buy, sell or hold?Divi's Laboratories on Monday saw a 49% year-on-year (YoY) fall in its consolidated net profit at Rs 356 crore for the quarter ended June 2...
- Divi’s Laboratories nosedives 20%, hits 52-week low on USFDA’s import alertIn a filing to BSE, the drug marker said that the USFDA has exempted the company from making ten drugs.
- Buy Divi’s Laboratories Ltd with a target of Rs 1865: Mitesh Thacker'Divi’s Laboratories Ltd is a 'BUY' call with a target of Rs 1865 and a stop loss of Rs 1774'
- Buy Divi’s Laboratories Ltd with a target of Rs 1,520: Mitesh Thacker"Divi’s Laboratories Ltd is a ‘BUY’ call with a target of Rs 1,520 and a stop loss of Rs 1,429."
- Buy Divi’s Laboratories Ltd with target price of Rs 1260: Ashwani GujralDivi’s Laboratories Ltd is a ‘BUY’ with a target of Rs 1260 and a stop loss of Rs 1195.
- Buy Divi’s Laboratories Ltd with target price of Rs 1065: Mitesh ThackerDivi’s Laboratories Ltd is a ‘Buy’ with a target of Rs 1065 and a stop loss of Rs 1014.
- Sell Divi’s Laboratories Ltd with a target of Rs 940: Mitesh Thacker"Divi’s Laboratories Ltd is a ‘SELL’ call with a target of Rs 940 and a stop loss of Rs 992."
- Buy Divi’s Laboratories Ltd with a target of Rs 1,005: Mitesh Thacker"Divi’s Laboratories Ltd is a ‘BUY’ call with a target of Rs 1,005 and a stop loss of Rs 949."
- Divi’s Laboratories tanks over 6% on weak Q4 earnings, downgradeThe company posted 16.75 per cent decline in its consolidated net profit at Rs 180.57 crore for the fourth quarter ended March 31.
Load More
